Lumos Delivers Several Pivotal Milestones in 1H FY26
Filed with ASX · · 8 pages · English
Summary by 6ix AI
Lumos Diagnostics Holdings Ltd. reports several significant milestones achieved in the first half of the financial year, including a major distribution agreement and completion of a clinical study for its product FebriDx. The company highlights a positive operating cash flow and substantial non-dilutive funding received during this period. Lumos also secured full Medicare reimbursement recognition across all U.S. jurisdictions, enhancing its market position.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Lumos Diagnostics Holdings Ltd. on 6ix
Earlier from Lumos Diagnostics
- Appendix 4D and Half Year Report
- Lumos Completes Enrolment Milestone for Paediatric Study
- Quarterly Activities/Appendix 4C Cash Flow Report
- Lumos Secures 100% US Medicare Reimbursement for FebriDx
- Lumos secures follow-on PKU contract with Aptatek
Later from Lumos Diagnostics
- Trading Halt
- US FDA Grants CLIA Waiver for FebriDx
- Lumos completes $20m placement and launches SPP
- Investor Presentation
- Lumos receives largest FebriDx order to date
Follow Lumos Diagnostics into a list and get an email when it puts out news.
Follow Lumos Diagnostics